Six peptides, ten conditions: HHS notice reaches the Federal Register

HHS’s peptide-compounding notice is now published in the Federal Register: 91 FR 68526–68527, October 30, 2026, document 2026-22192. That resolves the publication-status uncertainty in our October 29 analysis. It does not turn the six substances into FDA-approved medicines or place them on the final 503A bulks list. FDA does not review compounded drugs’ safety, effectiveness or quality before marketing.

Publication, policy and effective date are different questions

The official notice is a notice of availability, not a final rule adding substances to the bulks list. Its DATES section records publication on October 30; it states no separate effective date. We therefore do not describe October 30 as a new statutory authorization to compound.

There is a terminology mismatch worth keeping visible: the notice’s background calls the document a “draft,” while also referring to “this interim policy.” The HHS policy itself, pages 1–4, describes an interim enforcement position. The notice says it creates no rights and binds neither HHS nor the public. Publication does not remove those qualifications.

The notice accepts written comments through regulations.gov under docket HHS-OASH-2026-0496 until “2 weeks after date of publication.” Fourteen calendar days after October 30 is November 13, 2026; that date is our calculation, not a separately printed agency deadline or verified portal closing time. Comments and eventual FDA rulemaking are separate from the current enforcement policy.

The scope is conditional, not a six-peptide permission slip

HHS says it does not intend to take the described action against a State-licensed pharmacy, Federal facility or licensed physician when all the policy’s circumstances are present, until the substance is addressed in a final rule as included or not included on the 503A bulks list. The policy frames this discretion for substances that are not components of FDA-approved drugs, covered by applicable USP/NF monographs or already on the codified 503A bulks list. HHS can revisit the policy if safety signals or product-quality problems arise. A medspa or RN is not automatically a qualifying compounder because it serves patients.

Appendix A lists BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Appendix B narrows the relevant identities and routes. Its substance-specific conclusions describe:

BPC-157 acetate: subcutaneous, intramuscular, oral and topical dosage forms (PDF pages 5–6).
TB-500 acetate: subcutaneous or intramuscular injectable dosage forms (pages 6–7).
Epitalon acetate: subcutaneous or intramuscular injectable dosage forms dispensed in intermittent courses (pages 7–8).
Semax free base: intranasal use (page 8).
KPV acetate: topical and oral dosage forms (page 9).
MOTS-c acetate: subcutaneous or intramuscular injectable dosage forms (pages 9–10).

These are the policy’s stated limits, not treatment recommendations or a finding that an offered product meets them. A shared commercial name does not establish the correct chemical identity, formulation or route. Appendix B’s general discussion of injectable testing does not erase its substance-specific route restrictions.

Ten conditions sit behind the headline

Pages 2–4 of the HHS PDF set out ten circumstances. In condensed form, they require:

Inclusion in Appendix A.
The identity and route limitations described in Appendix B, including chemical structure, sequence, molecular weight and formula.
Sourcing from a section 510-registered facility and a valid COA with characterization and testing consistent with Appendix B.
FDA registration, CGMP and other FD&C compliance by the original manufacturer—not merely a distributor—with its physical facility location on the COA. An intervening registered repacker, relabeler or reseller must document manufacturer and COA validation.
Reporting products compounded, serious adverse events and quality issues to FDA and relevant States. Serious events are reported regardless of whether considered drug-related; patient labeling must explain the reporting procedure. Product reports include ingredient/strength, original manufacturer/facility identifier, dosage form and route.
The label statement: “This is a compounded drug product. Not for resale.”
Only a single active pharmaceutical ingredient listed in Appendix A—not peptide blends.
For oral dosage forms, documentation that the specific formulation supplied to the patient achieves adequate oral bioavailability in humans.
Only an FDA 510(k)-cleared syringe as a delivery device co-packaged with or containing the drug.
Compliance with all other applicable FD&C requirements, including sanitary compounding and section 503A’s patient-specific prescription requirement.

Appendix B also provides detailed testing criteria, manufacturer and batch information, validated analytical-method documentation and dosage-form-specific quality tests (pages 10–16). A generic “third-party tested” claim is not evidence that this record exists. We have not audited a pharmacy, supplier, lot or COA against these conditions.

What changes for a practitioner or business leader

The verified news is publication and the comment window—not drug approval, proof of clinical benefit, a 503B expansion, or clearance of a service menu. Supplier, formulation and patient-communication decisions still need product-specific pharmacy and qualified legal/clinical review. State scope-of-practice requirements are not resolved by this federal notice.

The policy’s Appendix B gives HHS’s reasoning and descriptions of evidence; this update does not independently validate those studies, exposure estimates or committee-vote accounts. Our earlier July analysis’s lack of independently verified vote records remains a separate gap. This article is original-source synthesis; qualified clinical and legal review remains outstanding.

Evidence record

Event date: 2026-10-30. Source review: 2026-10-30. Editorial publication: 2026-10-29. Original source links below retain their publication dates. These dates are not interchangeable. This is targeted source synthesis, not an exhaustive archive or a qualified clinical/legal review.

Revision history

30 October 2026: updated following publication of 91 FR 68526–68527. Read the official two-page notice and complete 16-page HHS policy; retained original editorial publication date and stable route. November 13 comment date is calculated; portal cutoff unverified. Published after editorial approval on 30 October 2026; no qualified clinical/legal review claimed. Report a proposed correction through Contact us; do not include patient data.